MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 20, 2008; DOI: 10.1124/mol.107.043620


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.043620v1
74/2/517    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, L.-C.
Right arrow Articles by Chang, J.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, L.-C.
Right arrow Articles by Chang, J.-Y.


Received for publication November 27, 2007.
Revised May 19, 2008.
Accepted for publication May 20, 2008.

TRANSCRIPTIONAL REPRESSION OF O6-METHYLGUANINE DNA METHYLTRANSFERASE GENE RENDERING CELLS HYPERSENSITIVE TO N,N'-BIS(2-CHLOROETHYL)-N-NITROSUREA IN CAMPTOTHECIN-RESISTANT CELLS

Li-Chen Ma 1, Ching-Chuan Kuo 1, Jin-Fen Liu 1, Li-Tzong Chen 1, Jang-Yang Chang 1*

1 National Institute of Cancer Research, National Health Research Institutes

* Address correspondence to: E-mail: jychang{at}nhri.org.tw

Abstract

O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl-adducts from the O6-guanine in DNA, and is a crucial defense against O6-alkylating agent-induced cytotoxicity. We demonstrated here that two camptothecin (CPT)-resistant cell lines (CPT30 and KB100) were more sensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea (BCNU) than their parental cells. Enhanced sensitivity to BCNU in these two CPT-resistant cells involved transcriptional repression of the MGMT gene. The mechanism of MGMT gene down-regulation in CPT-resistant cells was not through gene abnormality, mRNA stability, and CpG island hypermethylation. However, the high level of methyl-CpG-binding protein 2 (MeCP2) and di-methylation of H3K9 in the promoter region were found in CPT30 and KB100 cells. Furthermore, increased MeCP2 binding on MGMT promoter were also found to be corrected with MGMT gene silencing in short-term CPT treatment, thus, enhanced BCNU sensitivity in CPT-treated cells. Taken together, we suggest that CPT is able to suppress the transcription of MGMT gene through recruiting of MeCP2 and H3K9 di-methylation thus cause synergistic interaction with BCNU. These findings provide a possible explanation regarding why the combination of CPT and BCNU results in better objective response than single use alone. In addition, this study also suggest a new indication to treat patients whom refractory CPT derivatives with BCNU.


Key words: Resistance, Topoisomerases





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics